![Ongoing Phase II Study and ECHELON-2 and ALCANZA Phase III Trials of Brentuximab Vedotin in CD30-Positive Mature T-Cell Lymphomas | Research To Practice Ongoing Phase II Study and ECHELON-2 and ALCANZA Phase III Trials of Brentuximab Vedotin in CD30-Positive Mature T-Cell Lymphomas | Research To Practice](http://www.researchtopractice.com/sites/default/files/imagecache/slideshow_image/5mjc/slides/2011/5MJCHEM2013/3/1/Slide04.jpg)
Ongoing Phase II Study and ECHELON-2 and ALCANZA Phase III Trials of Brentuximab Vedotin in CD30-Positive Mature T-Cell Lymphomas | Research To Practice
![Gerytuit on X: "Wts New Echelon II Specialized, size L new ori. Wa:082138808791 #fnfjb #rbjb #fpjb https://t.co/WmSu8arNiP" / X Gerytuit on X: "Wts New Echelon II Specialized, size L new ori. Wa:082138808791 #fnfjb #rbjb #fpjb https://t.co/WmSu8arNiP" / X](https://pbs.twimg.com/media/Cj67HhiUgAIUHVP.jpg)
Gerytuit on X: "Wts New Echelon II Specialized, size L new ori. Wa:082138808791 #fnfjb #rbjb #fpjb https://t.co/WmSu8arNiP" / X
![Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial - The Lancet Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/7fa5a57c-2856-4685-b119-aa886cfde354/gr1_lrg.gif)